CD274 and nonpapillary renal cell carcinoma: Therefore, the clinical response observed in several tumor types, including ccRCC, after therapeutic targeting the PD-1/PD-L1 axis using specific checkpoint inhibitors might be partially dependent on PD-L1 blockade on TINK.